Oxford Ledge
Search
AEON Biopharma, Inc. (AMEX: AEON) is a biotechnology company trading at $0.67 (+0.8% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 11:10 UTC.
AEON Biopharma is a biopharmaceutical company developing ABP-450, a botulinum toxin complex designed as a biosimilar to the branded drug Botox for therapeutic medical indications. The company holds exclusive development and commercialization rights for ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories, and is pursuing approval through the FDA's biosimilar pathway. ABP-450 is already approved for aesthetic use in the United States under the brand name Jeuveau and is marketed in multiple international markets.
Summarized from AEON Biopharma, Inc.’s SEC filings · Read the filing ↗
| Quote | |
| Price | $0.67 |
| Change (1D) | +0.01 (+0.81%) |
| Volume | 15.1K shares |
| 52-week range | $0.62 – $1.45 |
| Returns | |
| 52-week return | +7.3% |
AEON Biopharma is a biopharmaceutical company developing ABP-450, a botulinum toxin complex designed as a biosimilar to the branded drug Botox for therapeutic medical indications.
AEON trades at $0.67, as of 2026-07-14.
SEC EDGAR filings and public market data feeds, fetched 2026-07-14 11:10 UTC. This page is also available as JSON at /api/data?ticker=AEON and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for AEON and 3,500+ tickers.
Create a free account — keep AEONGET /api/data?ticker=AEON
This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt